Status:
COMPLETED
Prevalence and Impact in Work Productivity of Gastroesophageal Reflux Disease (GERD) in Primary Care Patients With Upper Gastrointestinal (GI) Symptoms Using GerdQ
Lead Sponsor:
AstraZeneca
Conditions:
Gastroesophageal Reflux Disease
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of the study is to provide data on the GERD prevalence as percentage of patients with upper GI symptoms that are identified with GERD using the GerdQ Questionnaire. Furthermore the study a...
Eligibility Criteria
Inclusion
- Patients with upper-GI symptoms the last week prior visiting the investigator
Exclusion
- History of oesophageal, gastric or duodenal surgery
- Treatment with NSAIDs/Acetylsalicylic acid within the last week prior to the study visit
- PPI use for healing of NSAIDs induced ulcer or for HP eradication
Key Trial Info
Start Date :
July 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
889 Patients enrolled
Trial Details
Trial ID
NCT00914342
Start Date
July 1 2009
End Date
December 1 2009
Last Update
December 29 2009
Active Locations (54)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Pátrai, Achaias, Greece
2
Research Site
Mesologgion, Aitoloakarnaniaia, Greece
3
Research Site
Naupaktos, Aitoloakarnaniaia, Greece
4
Research Site
Grinion, Aitoloakarnania, Greece